Treatment of diabetes

• US 6,770,272 B2
• Filed: 05/14/2002
• Issued: 08/03/2004
• Est. Priority Date: 12/12/1994
• Status: Expired due to Fees

• Current Assignee: BETH Israel Medical Center (Mount Sinai Beth Israel)
• Original Assignee: BETH Israel Medical Center (Mount Sinai Beth Israel)
• Inventors: Strom, Terry B., Zheng, Xin Xiao, Steele, Alan
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US10/145,481
• Publication Number:
  US 20020173628A1
• Time in Patent Office: 812 Days
• Field of Search: 424/85.1, 424/85.2, 514/2, 514/8, 514/12, 514/866, 530/402
• US Class Current: 424/85.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/2026 IL-4
• CPC Class Codes: A61K 38/2066 IL-10
• CPC Class Codes: A61K 38/38 Albumins
• CPC Class Codes: A61K 38/45 Transferases (2)
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: C07K 16/46 Hybrid immunoglobulins hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00
• CPC Class Codes: C07K 2317/71 Decreased effector function due to an Fc-modification
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/02 containing a signal sequence
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/75 containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
• CPC Class Codes: C12N 15/62 DNA sequences coding for fusion proteins
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.

Claims

1. A method for treating, Type I diabetes, in a patient, the method comprising administering to the patient a therapeutically effective amount of a chimeric protein comprising interleukin-10 (IL-10) and a polypeptide that increases the circulating half-life of the chimeric protein relative to that of IL-10 alone, wherein administration of the chimeric protein is efficacious the treatment of Type I diabetes.

2. The method of claim 1, wherein the polypeptide comprises a hinge region of an IgG molecule.

3. The method of claim 1, wherein the polypeptide comprises albumin, or a porcine or rodent glycosyltransferase or α

-1,3-galactosyltransferase.

4. The method of claim 1, wherein the polypeptide comprises the Fc region of an IgO molecule but lacks an IgG variable region.

5. The method of claim 4, wherein the polypeptide thither comprises a hinge region of an IgG molecule.

6. The method of claim 4, wherein the Fc region is lytic.

7. The method of claim 4, wherein the Fc region is non-lytic.

8. The method of claim 4, wherein the Fc region includes a mutation that inhibits complement fixation and high affinity binding to an Fc receptor by the protein.

9. The method of claim 1, wherein the chimeric protein is administered to the patient with a pharmaceutically acceptable carrier.